USPTO serial 87817321
NEURIMMUNE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 17, 2020
- Examiner
- HILL, JAMES T
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NEURIMMUNE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Janice Housey
4 Weems Lane #240Winchester, VA 22601United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemical preparations for industrial purposes; chemical preparations for scientific purposes other than for medical or veterinary use; chemical preparations for use in photography; biological materials other than for medical or veterinary purposes, namely, biological preparations for use in industry and science; biological preparations for use in cell cultures other than for medical or veterinary use; peptide substrates used in analyzing and detecting certain toxins in chemical products and foodstuffs for clinical or medical laboratory use; polypeptides for use in diagnostic and therapeutic agents for non-medical purposes; chemical catalysts to accelerate organic reactions for biochemical processes, other than for medical or veterinary use; chemical compounds to accelerate chemical reactions; chemical preparations in the nature of activator enzymes for use in protein engineering and manufacturing | ACTIVE | — |
| 005 | pharmaceutical preparations for treating diseases of the nervous system, infectious diseases, neoplasms, diseases of the immune system, endocrine and metabolic diseases, diseases of the circulatory system, diseases of the eye; veterinary preparations for treating diseases of the nervous system, infectious diseases, neoplasms, diseases of the immune system, endocrine and metabolic diseases, diseases of the circulatory system, diseases of the eye; pharmaceutical preparations for immunotherapeutic purposes; pharmaceutical agents for the removal of tumors; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations, namely, immunogens; pharmaceutical preparations, namely, antibodies for use in disease testing; vaccines; diagnostic preparations for medical purposes in the form of epitopes for detection of anomalies in proteins; pharmaceutical preparations, namely, synthetic peptides for use in the treatment of diseases of the CNS, metabolic diseases, cardiovascular diseases, cancer, psychiatric diseases, infections; sanitary preparations for medical use; biological pharmaceutical preparations for medical use being for the treatment of diseases of the CNS, metabolic diseases, cardiovascular diseases, cancer, psychiatric diseases, infections; biocides; diagnostic preparations for medical and veterinary purposes; sanitary towels for hygiene purposes; dietetic foods adapted for medical use; dietetic beverages adapted for medical use; biological preparations in the nature of protein antibodies targeting specific epitopes of proteins for use in the treatment of diseases of the CNS, metabolic diseases, cardiovascular diseases, cancer, psychiatric diseases, infections, immunologic diseases, inflammatory diseases, respiratory diseases, psychological diseases for medical purposes; antibacterial preparations, namely, antibacterial substances for medical purposes, antibacterial pharmaceuticals; biopharmaceutical preparations for the treatment of cancer; protein dietary supplements | ACTIVE | — |
| 042 | monitoring, inspection, and analysis of biologically active chemical substances for quality control purposes; research on pharmaceutical products, cosmetics and foodstuffs for others; consultancy and information services in the field of monitoring and inspection for the quality control and analysis of biologically active chemical substances; research in the field of medical treatment and medical methods; research in the fields of biotechnology and antibodies; medical and scientific research information in the field of clinical trial testing and research in medical treatment; research in the field of sanitary care; monitoring and inspection of biological synthesis and pharmaceutical manufacturing for quality control and scientific research purposes and research in the field of biology; computer software design; computer programming; maintenance of computer software; design and development of computer hardware; development of computer software; consultancy and provision of information relating to quality control of pharmaceutical preparations; scientific research in the field of cancerous diseases; scientific research relating to chemistry | ACTIVE | — |
| 044 | medical services; medical services in the field of immunity; provision of medical information; medical examinations, namely, physical examination for medical purposes; preparation of medicines, namely, pharmaceutical compounding services and dispensing of medicines in the nature of pharmaceuticals; nutritional and dietary consultancy; consultancy and provision of information in the field of sanitary care, namely, providing sanitary health care information; veterinary services; beauty salon services; care services for animals, namely, veterinary care services; hygienic care services being medical services; consultancy and provision of medical information relating to the operation, preparation, administration and dosage of pharmaceutical preparations; advisory services relating to the administration of pharmaceuticals and the preparation of pharmaceutical prescriptions by pharmacists; providing medical information to healthcare professionals and patients in the form of compiled medical reports in the field of diagnostic, prophylactic and therapeutic properties of pharmaceuticals; drug use screening services for medical purposes; medical services, namely, information services relating to health care | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Neurimmune Holding AG
- Other trademarks owned by Neurimmune Holding AG
- Other trademarks owned by Neurimmune Holding AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NEURIMMUNE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 17, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 19, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 19, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 19, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 12, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 12, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 12, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 12, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 12, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 12, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 10, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 10, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 10, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 21, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 21, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 21, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 21, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 21, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 21, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 21, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 21, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 21, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 17, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 1, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 1, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 12, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 27, 2020 | XAAP | EXAMINER'S AMENDMENT AFTER PUB APPROVAL | — |
| Jul 27, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2020 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Jul 27, 2020 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jul 21, 2020 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Jul 21, 2020 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Jul 20, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| May 26, 2020 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Apr 21, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 18, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Apr 18, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 18, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 3, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 1, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 1, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 1, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 13, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 11, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 11, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 11, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 30, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 4, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 4, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 15, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 27, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 27, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 27, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 16, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 15, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 15, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 22, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 8, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 6, 2018 | NWAP | NEW APPLICATION ENTERED | — |